Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). And its at least possible that OCGN could wind up being a winner. Nasdaq Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Part of the proceeds will be used to support its partnership with Bharat. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. I will concede this: The one great thing about the stock market is there is a style for everyone. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. Source: Chart courtesy of StockCharts.com. Plus500. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The Motley Fool->. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. That's right -- they think these 10 stocks are even better buys. The average Ocugen stock price for the last 52 weeks is 2.10. The Ocugen deal is a way to salvage some limited value. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. That doesnt mean success is guaranteed. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Investing is always a game of balancing risk and reward. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Do not expect a recovery in Ocugen stock. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. Here are three prudent steps to take. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. The median estimate. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. At the beginning of 2020, Ocugen shares were trading at just 47 cents. If they invent a miracle treatment for a condition, the money will find its way to the stock. It has no treatments to offer the market. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Unfortunately for longs, OCGN is much closer to the worst of conditions. In that list, you can even include penny-stock trader. At the time, Ocugen was left for dead. That said, for investors who understand the potential downside, there is an intriguing story here. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. 1125 N. Charles St, Baltimore, MD 21201. OCGN does not even appear to have an apparent reason to exist. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Most biotech companies have intriguing stories on paper; Ocugen is no different. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Custom BMW. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Keith Speights has no position in any of the stocks mentioned. The potential synergies of such a union do not seem clear. However, when that occurred, Ocugen stock lost most of its value. The company stated that it will pursue a path to file for full FDA approval of Covaxin. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. The stock had gained some traction after they announced the. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. While anything is possible, I would not anticipate a miracle here. Honestly, OCGN stock is unlikely to survive. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. But there is no question some big-name stocks performed better than others along the way. The FDA's decision not to issue EUA really wasn't all that surprising, though. Ocugen Inc. is a clinical stage biopharmaceutical company. Keith Speights has no position in any of the stocks mentioned. The company initiated its Phase 3 trial of OCU300 back in July 2018. The biotech stock promptly crashed by more than 30%. Start trading Options with Saxo today. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Do Not Sell My Personal Information (CA Residents Only). Copy and paste multiple symbols separated by spaces. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. All rights reserved. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. 2023 InvestorPlace Media, LLC. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The Motley Fool has no position in any of the stocks mentioned. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Typically, I care little about financials with biotechs. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. The content is intended to be used for informational purposes only. Pricing likely would be favorable, given the lack of alternative treatments. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. If Ocugen goes up, you can still profit. The Motley Fool->. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Type a symbol or company name. It brings in no revenue. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. But just because a company does not have crippling debt doesnt mean its a buy. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. Investors need to understand the risk profile here. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. In this case, shares rallied about four-fold in just a few days. *Average returns of all recommendations since inception. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. If you missed that action, you missed all the gains. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." Even before that point, the most promising candidates generally can find funding. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization.